M18-891 Phase 3 JAK monotherapy atopic dermatitis adolescents&adults
Research type
Research Study
Full title
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
IRAS ID
247127
Contact name
Michael Ardern-Jones
Contact email
Eudract number
2018-001383-28
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in patients who require systemic anti-inflammatory treatments taken by mouth or injection through the skin or vein.
This is a phase 3 study for adolescent (12-17 years of age) and adult (18-75 years of age) patients with moderate to severe AD who are candidates for systemic treatment. Patients will receive treatment with upadacitinib/placebo.
Upadacitinib is an investigational drug currently being developed for the treatment of AD. This study will evaluate how well upadacitinib works within the body and how safe it is compared to placebo (an inactive substance).
The study is double-blinded which means neither the patient nor the study Doctor will know what treatment regimen has been assigned.
The study consists of a 35-day screening period, a 16-week double-blind treatment period, followed by a Blinded Extension Period for total treatment of up to 136 weeks, and a 30-day Follow-up Visit.
Approximately 810 patients will be enrolled in the study in approximately 185 sites worldwide.
Patients will attend regular study visits at the hospital or clinic. The effect of the treatment on the skin will be checked by dermatologic assessments, blood tests, checking for side effects and completing questionnaires.
There is an additional optional blood test to see why some people respond better than others to the drug.
There are also optional sub-studies to photograph the skin and to monitor movement during sleep. Patients will need to sign a consent form to participate in these sub-studies.REC name
South Central - Berkshire Research Ethics Committee
REC reference
18/SC/0421
Date of REC Opinion
4 Sep 2018
REC opinion
Favourable Opinion